Aspen Pharmacare Holdings Limited
Aspen Pharmacare Holdings Limited (APNHY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
apnhy · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Aspen Pharmacare Holdings Limited (APNHY) measures how much investors pay for each dollar of the company's trailing earnings. APNHY's current PE ratio of N/A is calculated by dividing its stock price of $9.03 by its TTM earnings per share of -$4.50.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%19.4x
MedianQ3 · 75%38.4x
Max
At N/A, APNHY's current P/E is lower than in 0% of its annual fiscal year readings over the past 19 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Aspen Pharmacare Holdings LimitedYou APNHY | $4.0B | N/A | — | -$4.50 |
 CanSino Biologics Inc. CASBF | $1.4B | 309.29x | +330.2% | $0.11 |
 China Medical System Holdings Limited CHSYF | $2.3B | 15.75x | -78.1% | $0.60 |
 Curaleaf Holdings, Inc. CURLF | $3.0B | N/A | — | -$0.93 |
 Dermapharm Holding SE DMPHF | $2.9B | 13.70x | -80.9% | $2.46 |
 Haw Par Corporation Limited HAWPY | $3.0B | 13.84x | -80.7% | $4.72 |
 HUTCHMED (China) Limited HMDCF | $2.5B | 6.86x | -90.5% | $0.53 |
Industry Average 5 peers with valid PE | — | 71.89x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | — | $-2.44 | — | |
2024-06-30 FY2024 | 22.73x | $9.91 | +45.6% | |
2023-06-30 FY2023 | 15.61x | $11.77 | +52.9% | |
2022-06-30 FY2022 | 10.21x | $14.32 | -33.9% | |
2021-06-30 FY2021 | 15.43x | $10.53 | +11.6% | |
2020-06-30 FY2020 | 13.82x | $10.22 | +88.4% | |
2019-06-30 FY2019 | 7.34x | $14.16 | -62.1% | |
2018-06-30 FY2018 | 19.35x | $13.17 | -24.6% | |
2017-06-30 FY2017 | 25.68x | $11.17 | -33.1% | |
2016-06-30 FY2016 | 38.41x | $9.42 | +12.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Aspen Pharmacare Holdings Limited (APNHY) measures how much investors pay for each dollar of the company's trailing earnings. APNHY's current PE ratio of N/A is calculated by dividing its stock price of $9.03 by its TTM earnings per share of -$4.50.
Frequently asked questions
APNHY pe ratio · 6 questionsAPNHY's current PE ratio is N/A as of 2026-06-08, based on a stock price of $9.03 and TTM EPS of -$4.50. Data sourced from Financial Modeling Prep via APNHY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aspen Pharmacare Holdings Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08